• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Tetanus - Pipeline Review, H2 2012 Product Image

Tetanus - Pipeline Review, H2 2012

  • Published: September 2012
  • 73 pages
  • Global Markets Direct

Tetanus – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Tetanus - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tetanus. Tetanus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Tetanus.
- A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Tetanus Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Tetanus 9
Tetanus Therapeutics under Development by Companies 11
Tetanus Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Tetanus Therapeutics – Products under Development by Companies 18
Tetanus Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Tetanus Therapeutics Development 20
Sanofi-Aventis 20
GlaxoSmithKline plc 21
Merck & Co., Inc. 22
Takeda Pharmaceutical Company Limited 23
Novartis Vaccines and Diagnostics, Inc. 24
Lipoxen PLC 25
Green Cross Corporation 26
LG Life Sciences, Ltd 27
Panacea Biotec Limited 28
iBio, Inc. 29
Tetanus – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
LipoTet - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
V501 + Menactra + Adacel - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TdaP Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Act-HIB® reconstituted with TRIPACEL® - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Tdap Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GSK-217744 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DTP-HepB-Polio-Hib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Quadracel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DtwP-HB-Hib (liq) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DTP-HepB/Hib Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Tetanus Toxin Monoclonal Antibody - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
V419 + Prevnar 13 + RotaTeq - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
Hexaxim - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GC-1107 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Pentavalent DTwP-HepB-Hib Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KD-332 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Easysix - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TAK-361S - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Tetanus Therapeutics – Drug Profile Updates 60
Tetanus Therapeutics – Discontinued Products 63
Tetanus Therapeutics - Dormant Products 64
Tetanus – Product Development Milestones 65
Featured News & Press Releases 65
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 65
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 66
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 66
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 67
Jan 30, 2008: GlaxoSmithKline Launches Two New Innovative Vaccines 67
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 68
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 68
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 69
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 70
Mar 15, 2005: GlaxoSmithKline Received Unanimous Favorable Recommendation by FDA Advisory Committee For Boostrix 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Tetanus, H2 2012 9
Products under Development for Tetanus – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sanofi-Aventis, H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Merck & Co., Inc., H2 2012 22
Takeda Pharmaceutical Company Limited, H2 2012 23
Novartis Vaccines and Diagnostics, Inc., H2 2012 24
Lipoxen PLC, H2 2012 25
Green Cross Corporation, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Panacea Biotec Limited, H2 2012 28
iBio, Inc., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Tetanus Therapeutics – Drug Profile Updates 60
Tetanus Therapeutics – Discontinued Products 63
Tetanus Therapeutics – Dormant Products 64

List of Figures
Number of Products under Development for Tetanus, H2 2012 9
Products under Development for Tetanus – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos